Posts

Update and perspectives on minor plant-derived cannabinoids of biomedical interest

Recently, the first publically-funded Latin American cannabinoid research network (CannaLatan, www.cyted.org/es/cannalatan), formed by academic investigators and pharma companies of different countries, was launched. CannaLatan aims to promote and boost the results obtained by the different partners of the consortium developing collaborative research and educational projects. The CannaLatan network is devoted to tackle the potential therapeutic applications of under-investigated phytocannabinoids and novel cannabinoid-based molecules, as well to clarify their undesired actions. Here we discuss one of the ongoing projects initiated by CannaLatan with the financial support of Fundación Canna (www.fundacion-canna.es/) , in which we address the anti-psychotic and cognitive actions of acidic forms of phytocannabinoids, namely THCa

Acute and residual mood and cognitive performance of young adults following smoked cannabis

Authors: Justin Matheson, Robert E. Mann, Beth Sproule, Marilyn A. Huestis, Christine M. Wickens, Gina Stoduto, Tony P. George, Jürgen Rehm, Bernard Le Foll, Bruna Brands Published in Science Direct  July 2020 Abstract Objectives To examine acute and residual mood and cognitive performance in young adult regular cannabis users following smoked cannabis. Methods Ninety-one healthy…

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors: Louise Arseneault, Mary Cannon, Richie Poulton, Robin Murray, Avshalom Caspi, Terrie E Moffitt
BMJ, 23 November 2002

The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. This study could not establish whether adolescent cannabis use w…